EL7.AI
Stocks•9 July 2026•
1 min read

Precigen Russell Index Removal Pressures Stock Despite Undervaluation Claims

Key Facts

1Precigen (PGEN) has been removed from several Russell indexes, potentially impacting trading volumes and pricing.
2Analysts estimate the stock is 55.3% undervalued with a fair value estimate of $12.45.

In a move reflecting the technical challenges facing small-cap biotech firms, Precigen has been removed from several key Russell indexes. According to reports, this exclusion is expected to negatively impact trading volumes and pricing due to forced selling by index-tracking funds. However, analysts maintain a bullish long-term view, estimating the stock is 55.3% undervalued with a fair value target of $12.45 based on the potential of its PAPZIMEOS treatment.

This technical pressure arrives as biotech stocks experience heightened volatility, where removal from benchmark indexes typically reduces institutional liquidity. Compared to industry peers, the gap between PGEN's current market valuation and fair value estimates highlights optimism regarding its clinical pipeline, though portfolio rebalancing pressures may dominate price action in the near term per market data.

Regarding broader catalysts, investors are looking ahead to the US ISM Services PMI data on July 6, 2026, which could influence risk appetite across the growth and biotechnology sectors.